Metformin Stada (Metformin Hydrochloride)

Metformin acts primarily by activating AMP‑activated protein kinase (AMPK), which suppresses hepatic glucose production and enhances peripheral insulin sensitivity. The result is reduced glucose output from the liver, increased glucose uptake by muscle cells, and modestly decreased intestinal glucose absorption, collectively improving glycaemic control.

The appropriate dose of Metformin Stada is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Dosage adjustments are made according to therapeutic goals and tolerability, and patients should follow the prescriber’s instructions without self‑adjusting the regimen.

The safety of Metformin Stada in pregnancy and lactation has not been definitively established. Healthcare providers weigh potential benefits against possible risks before prescribing it to pregnant or nursing women. Patients should discuss their specific situation with a qualified clinician to make an informed decision.

To order Metformin Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required cold‑chain handling), and import documentation.

Metformin is often the first‑line oral therapy for type 2 diabetes because it improves insulin sensitivity without causing weight gain and has a low risk of hypoglycaemia when used alone. Compared with sulfonylureas, it does not stimulate insulin release, and unlike insulin, it is administered orally and does not require injection.

Metformin Stada should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and excessive heat. Keep the product out of reach of children and avoid exposure to direct sunlight or humid environments to maintain its stability.

Metformin Stada is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water. The exact timing and frequency are determined by the prescribing clinician, who may adjust the regimen based on therapeutic response and tolerability.

The most serious adverse event associated with Metformin Stada is lactic acidosis, a rare but potentially fatal condition characterized by elevated blood lactate levels. Signs include unexplained fatigue, muscle pain, rapid breathing, and abdominal discomfort. Prompt medical attention is essential if these symptoms appear.

Metformin Stada is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, and those receiving radiographic studies with iodinated contrast agents unless renal function is re‑evaluated afterward. Clinicians should also exercise caution in individuals with significant hepatic disease or heart failure.